CA2844106A1 - Methods of treatment of retinal degeneration diseases - Google Patents
Methods of treatment of retinal degeneration diseases Download PDFInfo
- Publication number
- CA2844106A1 CA2844106A1 CA2844106A CA2844106A CA2844106A1 CA 2844106 A1 CA2844106 A1 CA 2844106A1 CA 2844106 A CA2844106 A CA 2844106A CA 2844106 A CA2844106 A CA 2844106A CA 2844106 A1 CA2844106 A1 CA 2844106A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- retinal
- wnt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 198
- 201000007737 Retinal degeneration Diseases 0.000 title claims description 158
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 158
- 230000004258 retinal degeneration Effects 0.000 title claims description 158
- 238000000034 method Methods 0.000 title abstract description 35
- 210000004027 cell Anatomy 0.000 claims abstract description 656
- 230000019491 signal transduction Effects 0.000 claims abstract description 208
- 230000002207 retinal effect Effects 0.000 claims abstract description 189
- 210000000130 stem cell Anatomy 0.000 claims abstract description 124
- 230000008672 reprogramming Effects 0.000 claims abstract description 104
- 230000001404 mediated effect Effects 0.000 claims abstract description 65
- 230000004913 activation Effects 0.000 claims abstract description 64
- 102000013814 Wnt Human genes 0.000 claims description 262
- 108050003627 Wnt Proteins 0.000 claims description 262
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 159
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 123
- 239000012190 activator Substances 0.000 claims description 70
- 230000004927 fusion Effects 0.000 claims description 56
- 239000003112 inhibitor Substances 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- 238000002347 injection Methods 0.000 claims description 39
- 239000007924 injection Substances 0.000 claims description 39
- 230000037361 pathway Effects 0.000 claims description 34
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 23
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 108010029485 Protein Isoforms Proteins 0.000 claims description 18
- 102000001708 Protein Isoforms Human genes 0.000 claims description 18
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- ALJIEVIJBAJISI-NCELDCMTSA-N (2e)-2-[(4-acetylphenyl)hydrazinylidene]-2-(3,3-dimethyl-4h-isoquinolin-1-yl)acetamide Chemical compound C1=CC(C(=O)C)=CC=C1N\N=C(\C(N)=O)C1=NC(C)(C)CC2=CC=CC=C12 ALJIEVIJBAJISI-NCELDCMTSA-N 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 230000003412 degenerative effect Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- DOKZLKDGUQWMSX-HKBQPEDESA-N (2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol Chemical compound C([C@@H](CO)NC=1C=2N=CN(CC=3C=CC(=CC=3)C=3C=CC=CC=3)C=2N=C(OC=2C=C3CCCC3=CC=2)N=1)C1=CC=CC=C1 DOKZLKDGUQWMSX-HKBQPEDESA-N 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- BHFFSIFXFHJJNJ-UHFFFAOYSA-N 5-(benzenesulfonyl)-n-[3-(dimethylamino)propyl]-2-ethylbenzenesulfonamide Chemical compound C1=C(S(=O)(=O)NCCCN(C)C)C(CC)=CC=C1S(=O)(=O)C1=CC=CC=C1 BHFFSIFXFHJJNJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000036443 AIPL1-related retinopathy Diseases 0.000 claims description 4
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 claims description 4
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 claims description 4
- 208000033810 Choroidal dystrophy Diseases 0.000 claims description 4
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 4
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 4
- 206010025412 Macular dystrophy congenital Diseases 0.000 claims description 4
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 claims description 4
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 4
- 208000027073 Stargardt disease Diseases 0.000 claims description 4
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 4
- 208000003571 choroideremia Diseases 0.000 claims description 4
- 201000006754 cone-rod dystrophy Diseases 0.000 claims description 4
- 208000006623 congenital stationary night blindness Diseases 0.000 claims description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 4
- 229960003964 deoxycholic acid Drugs 0.000 claims description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 4
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 4
- 208000014769 Usher Syndromes Diseases 0.000 claims 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 210000001525 retina Anatomy 0.000 abstract description 117
- 230000007910 cell fusion Effects 0.000 abstract description 75
- 102000015735 Beta-catenin Human genes 0.000 abstract 1
- 108060000903 Beta-catenin Proteins 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 129
- 241000699670 Mus sp. Species 0.000 description 119
- 210000001116 retinal neuron Anatomy 0.000 description 117
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 114
- 238000002054 transplantation Methods 0.000 description 87
- 108090000623 proteins and genes Proteins 0.000 description 86
- 230000014509 gene expression Effects 0.000 description 75
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 71
- 208000003098 Ganglion Cysts Diseases 0.000 description 54
- 208000005400 Synovial Cyst Diseases 0.000 description 54
- 102000004169 proteins and genes Human genes 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 52
- 210000002569 neuron Anatomy 0.000 description 46
- 108010054624 red fluorescent protein Proteins 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 45
- 230000004069 differentiation Effects 0.000 description 38
- 238000001727 in vivo Methods 0.000 description 36
- 230000006378 damage Effects 0.000 description 35
- 210000001671 embryonic stem cell Anatomy 0.000 description 34
- 210000004498 neuroglial cell Anatomy 0.000 description 34
- 210000001185 bone marrow Anatomy 0.000 description 32
- -1 e.g. Proteins 0.000 description 32
- 108091008695 photoreceptors Proteins 0.000 description 32
- 230000008929 regeneration Effects 0.000 description 32
- 238000011069 regeneration method Methods 0.000 description 32
- 210000004940 nucleus Anatomy 0.000 description 31
- 241000282414 Homo sapiens Species 0.000 description 27
- 210000000411 amacrine cell Anatomy 0.000 description 26
- 102000001267 GSK3 Human genes 0.000 description 25
- 239000002243 precursor Substances 0.000 description 25
- 102000008730 Nestin Human genes 0.000 description 24
- 108010088225 Nestin Proteins 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 23
- 210000004754 hybrid cell Anatomy 0.000 description 23
- 210000005055 nestin Anatomy 0.000 description 23
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 20
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 230000007850 degeneration Effects 0.000 description 18
- 210000002798 bone marrow cell Anatomy 0.000 description 16
- 230000001537 neural effect Effects 0.000 description 16
- 230000011664 signaling Effects 0.000 description 16
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 15
- 101150092239 OTX2 gene Proteins 0.000 description 15
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 15
- 239000003550 marker Substances 0.000 description 15
- 102000045246 noggin Human genes 0.000 description 15
- 108700007229 noggin Proteins 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 210000001082 somatic cell Anatomy 0.000 description 14
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 13
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 13
- 206010057430 Retinal injury Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 12
- 230000004438 eyesight Effects 0.000 description 12
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 210000000135 megakaryocyte-erythroid progenitor cell Anatomy 0.000 description 12
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 12
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 11
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 11
- 102000004330 Rhodopsin Human genes 0.000 description 11
- 108090000820 Rhodopsin Proteins 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 210000000608 photoreceptor cell Anatomy 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 108090000672 Annexin A5 Proteins 0.000 description 9
- 102000004121 Annexin A5 Human genes 0.000 description 9
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 9
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 9
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000003070 Statistical process control Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 102100029794 Urocortin-3 Human genes 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 101150030271 AXIN1 gene Proteins 0.000 description 7
- 102000051172 Axin Human genes 0.000 description 7
- 108700012045 Axin Proteins 0.000 description 7
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 7
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 7
- 102100022762 R-spondin-1 Human genes 0.000 description 7
- 102000050389 Syntaxin Human genes 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 210000003050 axon Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000002771 cell marker Substances 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000001328 optic nerve Anatomy 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 201000004569 Blindness Diseases 0.000 description 6
- 102000017944 Dishevelled Human genes 0.000 description 6
- 108050007016 Dishevelled Proteins 0.000 description 6
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 208000035199 Tetraploidy Diseases 0.000 description 6
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 102000005396 glutamine synthetase Human genes 0.000 description 6
- 108020002326 glutamine synthetase Proteins 0.000 description 6
- 238000003125 immunofluorescent labeling Methods 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 102100029855 Caspase-3 Human genes 0.000 description 5
- 108060006662 GSK3 Proteins 0.000 description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 5
- 101000609949 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Proteins 0.000 description 5
- 102100022338 Integrin alpha-M Human genes 0.000 description 5
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 101150010310 WNT-4 gene Proteins 0.000 description 5
- 101150109862 WNT-5A gene Proteins 0.000 description 5
- 101150019524 WNT2 gene Proteins 0.000 description 5
- 108700020986 Wnt-2 Proteins 0.000 description 5
- 102000052556 Wnt-2 Human genes 0.000 description 5
- 102000052549 Wnt-3 Human genes 0.000 description 5
- 108700020985 Wnt-3 Proteins 0.000 description 5
- 102000052548 Wnt-4 Human genes 0.000 description 5
- 108700020984 Wnt-4 Proteins 0.000 description 5
- 108700020483 Wnt-5a Proteins 0.000 description 5
- 102000043366 Wnt-5a Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000032459 dedifferentiation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 210000001900 endoderm Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 5
- 210000001020 neural plate Anatomy 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 5
- 230000007420 reactivation Effects 0.000 description 5
- 210000001164 retinal progenitor cell Anatomy 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000017423 tissue regeneration Effects 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- 101150096411 AXIN2 gene Proteins 0.000 description 4
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 101710110302 R-spondin-1 Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000013042 tunel staining Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010017009 CD11b Antigen Proteins 0.000 description 3
- 102000004354 CD11b Antigen Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108010051219 Cre recombinase Proteins 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 3
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100025304 Integrin beta-1 Human genes 0.000 description 3
- 102100039064 Interleukin-3 Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100020880 Kit ligand Human genes 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 102100022763 R-spondin-2 Human genes 0.000 description 3
- 101710110295 R-spondin-2 Proteins 0.000 description 3
- 102100022766 R-spondin-3 Human genes 0.000 description 3
- 101710110310 R-spondin-3 Proteins 0.000 description 3
- 102100022759 R-spondin-4 Human genes 0.000 description 3
- 101710110307 R-spondin-4 Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 102000000999 Secreted frizzled-related protein 1 Human genes 0.000 description 3
- 108010039445 Stem Cell Factor Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 108060008245 Thrombospondin Proteins 0.000 description 3
- 102000002938 Thrombospondin Human genes 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 3
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 3
- 101150003286 gata4 gene Proteins 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 210000001153 interneuron Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100035683 Axin-2 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000012756 BrdU staining Methods 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010003730 Cone Opsins Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000032578 Inherited retinal disease Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 210000005156 Müller Glia Anatomy 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 101150085386 PDE6B gene Proteins 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 241000278713 Theora Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- ITBGJNVZJBVPLJ-UHFFFAOYSA-N WAY-316606 Chemical compound FC(F)(F)C1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1S(=O)(=O)NC1CCNCC1 ITBGJNVZJBVPLJ-UHFFFAOYSA-N 0.000 description 2
- 108010047118 Wnt Receptors Proteins 0.000 description 2
- 102000006757 Wnt Receptors Human genes 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000001284 amacrine neuron Anatomy 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000005966 endogenous activation Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 101150002688 kremen1 gene Proteins 0.000 description 2
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000007801 sublethal irradiation Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- YICWDMKVBLRMMK-UHFFFAOYSA-N 5-(benzylamino)-1,2,4-thiadiazol-3-one Chemical compound S1NC(=O)N=C1NCC1=CC=CC=C1 YICWDMKVBLRMMK-UHFFFAOYSA-N 0.000 description 1
- WUCGGYNUXYGZLO-UHFFFAOYSA-N 8,11,14,17-tetraoxa-5,20,26-triazabicyclo[22.3.0]heptacosa-1(24),2,4,6,9,12,15,18,20,22-decaene-25,27-dione Chemical compound C1=CC=NC=COC=COC=COC=COC=CN=CC=CC2=C1C(=O)NC2=O WUCGGYNUXYGZLO-UHFFFAOYSA-N 0.000 description 1
- 102000000074 ADP-ribosyl Cyclase Human genes 0.000 description 1
- 108010080394 ADP-ribosyl Cyclase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 1
- 101710111837 Cyclic phosphodiesterase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010012667 Diabetic glaucoma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102000027587 GPCRs class F Human genes 0.000 description 1
- 108091008884 GPCRs class F Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 102100031922 Homeobox protein NANOG Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 1
- 101001128090 Homo sapiens Homeobox protein NANOG Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 101150068332 KIT gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010015179 Low Density Lipoprotein Receptor-Related Protein-6 Proteins 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 241001602730 Monza Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108700026371 Nanog Homeobox Proteins 0.000 description 1
- 102000055601 Nanog Homeobox Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101150101087 Nt5e gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 101150081664 PAX6 gene Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 101150116978 RPE65 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 101150114388 SLAMF1 gene Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 108091084789 TCF/LEF family Proteins 0.000 description 1
- 102000043043 TCF/LEF family Human genes 0.000 description 1
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 101150078250 Tcf3 gene Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 241000397921 Turbellaria Species 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 101150097457 Vcam1 gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010041332 Very Late Antigen Receptors Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 210000001056 activated astrocyte Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000007348 cell dedifferentiation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005968 exogenous activation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 102000048338 human CD244 Human genes 0.000 description 1
- 102000052645 human CD38 Human genes 0.000 description 1
- 102000048851 human CD44 Human genes 0.000 description 1
- 102000054189 human CD80 Human genes 0.000 description 1
- 102000049849 human CD86 Human genes 0.000 description 1
- 102000052088 human IL3RA Human genes 0.000 description 1
- 102000046661 human PECAM1 Human genes 0.000 description 1
- 102000046537 human SLAMF1 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960004439 pemirolast Drugs 0.000 description 1
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 210000001850 polyploid cell Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028396 retina morphogenesis in camera-type eye Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 208000001571 retinitis pigmentosa 1 Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 229950009638 tepoxalin Drugs 0.000 description 1
- 208000027223 tetraploidy syndrome Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176713.3 | 2011-08-05 | ||
| EP11176713A EP2554662A1 (en) | 2011-08-05 | 2011-08-05 | Methods of treatment of retinal degeneration diseases |
| PCT/EP2012/065327 WO2013020945A1 (en) | 2011-08-05 | 2012-08-06 | Methods of treatment of retinal degeneration diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2844106A1 true CA2844106A1 (en) | 2013-02-14 |
Family
ID=46826437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2844106A Abandoned CA2844106A1 (en) | 2011-08-05 | 2012-08-06 | Methods of treatment of retinal degeneration diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140199277A1 (enExample) |
| EP (2) | EP2554662A1 (enExample) |
| JP (1) | JP2014527407A (enExample) |
| KR (1) | KR20140068936A (enExample) |
| CN (1) | CN104011203A (enExample) |
| AR (1) | AR087471A1 (enExample) |
| AU (1) | AU2012293681A1 (enExample) |
| BR (1) | BR112014002718A8 (enExample) |
| CA (1) | CA2844106A1 (enExample) |
| CO (1) | CO7081142A2 (enExample) |
| IL (1) | IL230830A0 (enExample) |
| MX (1) | MX2014001475A (enExample) |
| RU (1) | RU2014108478A (enExample) |
| SG (1) | SG2014008080A (enExample) |
| WO (1) | WO2013020945A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012314330B2 (en) * | 2011-09-29 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for the treatment of degenerative retinal conditions |
| SG11201605833PA (en) | 2014-01-17 | 2016-08-30 | Sumitomo Chemical Co | Method for manufacturing ciliary margin stem cells |
| KR102612871B1 (ko) * | 2014-09-16 | 2023-12-13 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| RU2578526C1 (ru) * | 2014-12-25 | 2016-03-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа |
| RU2569481C1 (ru) * | 2014-12-25 | 2015-11-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа |
| KR101779932B1 (ko) * | 2015-09-15 | 2017-09-21 | 주식회사 스템랩 | 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR101674622B1 (ko) * | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
| CA3032153A1 (en) * | 2016-08-19 | 2018-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
| WO2018106369A2 (en) * | 2016-11-06 | 2018-06-14 | Nanoscope Technologies Llc | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
| EP3616120B1 (en) | 2017-04-27 | 2024-09-04 | Retinascan Limited | System and method for automated funduscopic image analysis |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| US20210139844A1 (en) * | 2017-06-15 | 2021-05-13 | University Of North Texas Health Science Center | Reprogramming fibroblasts to retinal cells |
| EP3668487A4 (en) * | 2017-08-20 | 2020-08-26 | The Regents of the University of California | MODULATION OF WNT5A TO TREAT GLAUCOMA |
| EP3773638A4 (en) * | 2018-04-06 | 2022-04-06 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR TREATING LOSS OF VISION BY GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS |
| EP3937955A4 (en) * | 2019-03-15 | 2022-12-07 | The Schepens Eye Research Institute, Inc. | ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES |
| CN110706164A (zh) * | 2019-09-03 | 2020-01-17 | 北京爱博同心医学科技有限公司 | 基于增强现实的管状视野图像变形显示方法及眼镜 |
| US20230034053A1 (en) * | 2019-09-25 | 2023-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Metabolic rescue of retinal degeneration |
| KR20210119766A (ko) * | 2020-03-25 | 2021-10-06 | 서울대학교병원 | 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물 |
| KR102655748B1 (ko) * | 2023-06-08 | 2024-04-05 | 충북대학교 산학협력단 | 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법 |
| KR102655735B1 (ko) * | 2023-06-09 | 2024-04-05 | 충북대학교 산학협력단 | 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포 |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6128654A (en) | 1997-02-14 | 2000-10-03 | Advanced Micro Devices, Inc. | Method and apparatus for transmitting multiple copies by replicating data identifiers |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | グリコーゲンシンターゼキナーゼ３のインヒビター |
| AU784748B2 (en) | 1999-12-17 | 2006-06-08 | Novartis Vaccines And Diagnostics, Inc. | Bicyclic inhibitors of glycogen synthase kinase 3 |
| ATE384704T1 (de) | 1999-12-17 | 2008-02-15 | Novartis Vaccines & Diagnostic | Pyrazin-basierte hemmer der glycogen-synthase- kinase 3 |
| CN100506801C (zh) | 2000-09-06 | 2009-07-01 | 诺华疫苗和诊断公司 | 糖元合成酶激酶3的抑制剂 |
| ES2302106T3 (es) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
| JP4523271B2 (ja) | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
| JP4656838B2 (ja) | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| JP2005525362A (ja) | 2002-03-01 | 2005-08-25 | カイロン コーポレイション | 虚血の処置のための方法および組成物 |
| US20050129665A1 (en) | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7838290B2 (en) * | 2002-07-25 | 2010-11-23 | The Scripps Research Institute | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| DE60333762D1 (de) | 2002-08-23 | 2010-09-23 | Novartis Vaccines & Diagnostic | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
| JP2006506383A (ja) | 2002-10-21 | 2006-02-23 | カイロン コーポレイション | グリコーゲンシンターゼキナーゼ３のインヒビター |
| EP1624758A4 (en) * | 2003-05-02 | 2007-03-07 | Scripps Research Inst | HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS |
| KR20060056377A (ko) | 2003-08-13 | 2006-05-24 | 카이론 코포레이션 | Ｇｓｋ-3 억제제 및 그것의 사용 |
| JP2008512376A (ja) * | 2004-09-03 | 2008-04-24 | ザ・スクリプス・リサーチ・インステイチユート | 単離された系統陰性造血幹細胞及びこれを用いた治療方法 |
| US7850960B2 (en) * | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| JP5173442B2 (ja) | 2005-02-24 | 2013-04-03 | ザ スクリプス リサーチ インスティチュート | 未熟児網膜症及び関連網膜症疾患の治療のための方法 |
| US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
| CA2613889A1 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| EA201070022A1 (ru) * | 2007-06-15 | 2010-06-30 | Гарнет Байотерапьютикс Инк. | Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro |
| EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
| GB0816577D0 (en) * | 2008-09-11 | 2008-10-15 | Axordia Ltd | Growth factor |
| EP2486126B1 (en) * | 2009-10-06 | 2017-12-06 | SNU R & DB Foundation | Method for differentiation into retinal cells from stem cells |
-
2011
- 2011-08-05 EP EP11176713A patent/EP2554662A1/en not_active Withdrawn
-
2012
- 2012-08-06 KR KR1020147006060A patent/KR20140068936A/ko not_active Withdrawn
- 2012-08-06 SG SG2014008080A patent/SG2014008080A/en unknown
- 2012-08-06 US US14/237,297 patent/US20140199277A1/en not_active Abandoned
- 2012-08-06 MX MX2014001475A patent/MX2014001475A/es not_active Application Discontinuation
- 2012-08-06 AU AU2012293681A patent/AU2012293681A1/en not_active Abandoned
- 2012-08-06 EP EP12756386.4A patent/EP2739723A1/en not_active Withdrawn
- 2012-08-06 AR ARP120102872A patent/AR087471A1/es unknown
- 2012-08-06 JP JP2014523346A patent/JP2014527407A/ja active Pending
- 2012-08-06 BR BR112014002718A patent/BR112014002718A8/pt not_active IP Right Cessation
- 2012-08-06 WO PCT/EP2012/065327 patent/WO2013020945A1/en not_active Ceased
- 2012-08-06 CN CN201280049453.2A patent/CN104011203A/zh active Pending
- 2012-08-06 CA CA2844106A patent/CA2844106A1/en not_active Abandoned
- 2012-08-06 RU RU2014108478/10A patent/RU2014108478A/ru not_active Application Discontinuation
-
2014
- 2014-02-05 IL IL230830A patent/IL230830A0/en unknown
- 2014-03-05 CO CO14047158A patent/CO7081142A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104011203A (zh) | 2014-08-27 |
| AR087471A1 (es) | 2014-03-26 |
| EP2739723A1 (en) | 2014-06-11 |
| US20140199277A1 (en) | 2014-07-17 |
| RU2014108478A (ru) | 2015-09-10 |
| JP2014527407A (ja) | 2014-10-16 |
| WO2013020945A1 (en) | 2013-02-14 |
| AU2012293681A1 (en) | 2014-03-06 |
| NZ621345A (en) | 2015-09-25 |
| IL230830A0 (en) | 2014-03-31 |
| MX2014001475A (es) | 2014-07-22 |
| CO7081142A2 (es) | 2014-10-10 |
| BR112014002718A2 (pt) | 2017-06-13 |
| SG2014008080A (en) | 2014-03-28 |
| WO2013020945A9 (en) | 2013-04-04 |
| EP2554662A1 (en) | 2013-02-06 |
| BR112014002718A8 (pt) | 2017-06-20 |
| KR20140068936A (ko) | 2014-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140199277A1 (en) | Methods of Treatment of Retinal Degeneration Diseases | |
| Sanges et al. | Wnt/β-catenin signaling triggers neuron reprogramming and regeneration in the mouse retina | |
| Sanges et al. | Reprogramming Müller glia via in vivo cell fusion regenerates murine photoreceptors | |
| Xiao et al. | Neurotrophic factor GDNF promotes survival of salivary stem cells | |
| US10787641B2 (en) | Therapeutic use of CD31 expressing cells | |
| JP2021530232A (ja) | 免疫改変された多能性細胞から分化させた細胞 | |
| US20150250824A1 (en) | Methods and compositions for expansion of stem cells and other cells | |
| Huang et al. | Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart | |
| JPWO2018164240A1 (ja) | 網膜色素上皮細胞の製造方法 | |
| US20210040452A1 (en) | Hematopoietic cells and methods of using and generating the same | |
| JP2025028314A (ja) | 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬 | |
| ES2382357T3 (es) | Células de tipo mieloide transfectadas para el tratamiento de retinopatía de la prematuridad y enfermedades relacionadas | |
| Zhang et al. | Neuritin promotes bone marrow-derived mesenchymal stem cell migration to treat diabetic peripheral neuropathy | |
| Ahamad et al. | Bone marrow stem cells, aging, and age-related diseases | |
| KR20120060201A (ko) | 기능적으로 분화된 체세포의 연장된 자기재생을 유도하는 방법 | |
| Tsupykov et al. | Long‐term fate of grafted hippocampal neural progenitor cells following ischemic injury | |
| US20200347352A1 (en) | Methods and system of human hemogenic reprograming | |
| Huang et al. | Adult human periodontal ligament-derived stem cells delay retinal degeneration and maintain retinal function in RCS rats | |
| CA2628530C (en) | Novel stem cells, nucleotide sequences and proteins therefrom | |
| NZ621345B2 (en) | Methods of treatment of retinal degeneration diseases | |
| EP3231434A1 (en) | Method of treatment of parkinsonism | |
| Morad | Mesenchymal stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis | |
| WO2022009969A1 (ja) | 網膜色素上皮細胞の移植用生着促進剤 | |
| Pesaresi | Exogenous expression of chemokine receptors improves mouse mesenchymal stem cell migration towards the degenerating retina | |
| Alsolami | The Role of WNT-beta-Catenin Pathway in the Specification of Primitive and Definitive Hematopoiesis during Differentiation of Pluripotent Stem Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20170808 |